Published on 09 Apr 2013
Sign up for email alerts to receive notifications of new articles published in Clinical Medicine Insights: Circulatory, Respiratory and Pulmonary Medicine
Chronic obstructive pulmonary disease (COPD) is the fourth leading cause of death worldwide and is projected to be the third by 2020. COPD is characterized by chronic airflow limitation caused by airway inflammation and parenchymal destruction that is usually progressive. Inhaled bronchodilators continue to be the mainstay of the current management of COPD. Safety and efficacy data of the recently approved medications including aclidinium, glycopyrronium, roflumilast, and indacaterol are reviewed here.
PDF (538.25 KB PDF FORMAT)
RIS citation (ENDNOTE, REFERENCE MANAGER, PROCITE, REFWORKS)
BibTex citation (BIBDESK, LATEX)
My experience with Libertas Academica publications has indicated that Libertas Academica has not only implemented a highly efficient reviewer system, which provides candid and valuable comments on manuscripts, but also assembled a dedicated editorial production team, which is constantly striving for world-best practice. I recommend Libertas Academica publications highly.